Foreign participants at the 16th Asia Pharma Expo foresee a bright future for Bangladesh’s pharmaceutical industry, given its ...

The implementation of the revised Schedule M marks a critical step towards enhancing the quality and safety of pharmaceutical ...

With a 10% tariff making Chinese products costlier, US importers may turn to Indian companies as cost-effective alternatives.

The finest minds from the pharma firmament will also be sharing insights on the changing landscape and on the new imperatives ...

China geopolitical tensions, China's Fosun Pharmaceutical is in discussions with three global private equity firms to sell ...

Drugmakers must complete a gap analysis and submit their compliance strategy to extend Schedule M implementation. Small and ...

Astrazeneca Pharma India advanced 1.21% to Rs 7557.05 after the company's standalone net profit surged to Rs 54.68 crore in Q3 FY25 as compared with Rs 15.80 crore in Q3 FY24.

The Union Health Ministry has conditionally extended the deadline for implementing the revised Schedule M, a set of good manufacturing practices for small and medium pharmaceutical companies, till ...

NATCO Pharma Ltd on Wednesday reported a 37.75 per cent decline in consolidated net profit to Rs 132.4 crore in the December ...

India's Ministry of Health & Family Welfare extends the Schedule M implementation deadline for small & medium pharma firms with turnover under Rs 250 crore till December 31, 2025.

Pharmexcil announces business delegation to Zambia, Tanzania & DR Congo from March 24 to April 1: Shardul Nautiyal, Mumbai Wednesday, February 12, 2025, 08:00 Hrs [IST] The Pharma ...

Lupin shares saw a strong recovery on February 12 after the company reported solid Q3 FY25 earnings. The stock, which ...